Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim and Peripheral Stem Cell Transplantation in High-Risk AML or CML
NCT00002833Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 1994
- Primary completion
- Apr 2002
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of filgrastim in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 1994; status: completed.
02
Drugs
filgrastim
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00002833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002833.